Kineta, Inc. announced at the American Association for Cancer Research (AACR) in San Diego, CA an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA®? (pembrolizumab), in patients with advanced solid tumors. The poster presentation #CT068: "Interim results of the ongoing phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors" was presented Monday, April 8, 2024 and reported the following findings (the data cutoff date was February 28, 2024).

Monotherapy Dose Escalation (3-300 mg KVA12123 Q2W); Of 21 patients enrolled, 12 received at least one baseline and one follow-up scan; Best overall response (BOR) in 9 of 12 patients with at least one follow-up scan is stable disease with a mean duration of 15 weeks; One patient with non-small cell lung cancer that failed 6 prior lines of therapy, including checkpoint inhibitor (CPI) therapy, has experienced stable disease lasting 28 weeks; Nine patients remain on-treatment Combination Therapy Dose Escalation (30-100 mg KVA12123 SecondW, 400 mg pembrolizumab Q6W); BOR in 2 of 3 patients with at least one follow up scan is: Partial Response in 1 mucoepidermoid carcinoma patient with a 54% reduction in target lesions and a complete response in non-target lesions; Stable disease in 1 renal cell carcinoma patient that had progressed on prior CPI therapy with a 24% reduction in target lesions; Eight patients remain on-treatment Biomarkers; Dose-dependent induction of on-target pro-inflammatory cytokines and chemokines; Dose-dependent increases in activated non-classical monocytes, CD4+ and CD8+ T cells, and NK cells; Safety; No DLTs observed in any patient at any dose level; No evidence of cytokine release syndrome in any dose level. No evidence of cytokine released syndrome in any patient at any dose levels. KVA12123 is a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody infusion drug being evaluated in a Phase 1/2 clinical trial for patients with advanced solid tumors.

Competitive therapies targeting VISTA have demonstrated either poor monotherapy anti-tumor activity in preclinical models or induction of cytokine release syndrome (CRS) in human clinical trials. Through the combination of unique epitope binding and an optimized IgG1 Fc region, KVA12123 demonstrates strong monotherapy tumor growth inhibition in preclinical models without evidence of CRS in clinical trial participants. Such forward-looking state ments are subject to a number of material risks and uncertainties including, but not limited to: Kineta's ability to successfully initiate and complete clinical trials; the difficulty in predicting the time and cost of development of Kineta's product candidates; Kineta's plans to research, develop and commercialize its current and future product candidates, including, but not limited to, KVA12123; the timing and anticipated results of Kineta's planned pre-clinical studies and clinical trials and the risk that the results of Kineta's pre-clinical studies and clinical trial may not be predictive of future results in connection with future studies or clinical trials; the timing of the availability of data from Kineta's clinical trials; the timing of The availability of data from Kineta' clinical trials; the timing Of the availability of data fromKineta's clinical trials; the availability of data from Kinet's clinical trials; the timing the availability of data from Kinette's clinical trials; the availability the availability of the data from Kineta's clinical trial; the availability of data from company's clinical trials; the availability.

the availability of data from KinETA's clinical trials; the availability to the availability of data from KinET's clinical trials; the availability for data from Kineta's clinical studies; the availability of data from the availability of the availability of the availability of data from the clinical trials; the availability of the availability of Kineta's clinical trials; The data from Kineta's clinical Trial of the availability of the availability the availability of the availability of company's clinical trials; the available data from Kineta's clinical clinical trials; the availability of Kineta's patients with the availability of the availability of KVA12123 Second Quarter trials; the availability of the available to the availability of the availability of The company's clinical trials; the company's clinical trials; the data from company's clinical trials, the availability of the availability of its clinical trials; the availability of its clinical trials, the availability of Kineta'sclinical trials.